Intro Pullout Text Widget

Drug and Therapeutics Bulletin

(DTB) covers practical, independent and evidence-based information on drugs, medication and prescribing.

Drug and Therapeutics Bulletin (DTB) publishes independent evaluations and practical advice on individual treatments and the overall management of disease. DTB summarises the best available evidence to enable doctors, pharmacists and other healthcare professionals to make informed and unbiased choices to help patients get the best care. DTB is wholly independent of the pharmaceutical industry, government and regulatory authorities and is also free of advertising and other forms of commercial sponsorship.

DTB publishes regular podcasts discussing highlights from its issues. Subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

Current Issue

About

DTB adheres to the highest possible industry standards concerning publication ethics. Content is commissioned and undergoes a rigorous and transparent editorial process: articles are peer-reviewed and authors are required to declare and publish any conflicts of interest.

DTB publishes opinion pieces, commentaries, summaries of recently published evidence as well as clinical reviews and articles on new medicines. Read more about our content in the Welcome to the new Drug and Therapeutics Bulletin Editorial.

As a founder member of The International Society of Drug Bulletins, Drug and Therapeutics Bulletin is also completely independent of: the pharmaceutical industry, government and regulatory authorities, advertising and other forms of commercial sponsorship.

Editorial policies

Publication information

Twitter Feed

DTB_BMJ @DTB_BMJ

September's podcast 🎙️includes the FDA's controversial decision to license aducanumab for Alzheimer's disease; barriers to using shorter antibiotic courses in primary care; impact of medicines on oral health/dental care; and NICE on shared decision making.
https://t.co/VyAQ67pbRd https://t.co/AQpeWYCAH6

View on Twitter

DTB_BMJ @DTB_BMJ

Will reclassification of a progestogen-only contraceptive from a prescription only medicine (POM) to a pharmacy medicine (P) help address problems with access to contraceptive services?

Read our editorial: Desogestrel POM to P: for the few not the many?

https://t.co/nLVBcbjBPg https://t.co/ztkagD9EhA

View on Twitter

DTB_BMJ @DTB_BMJ

Osteoporosis and fracture risk associated with corticosteroids used for asthma - read our DTB Select overview of two case–control studies in nearly 70 000 people with asthma 🆕

https://t.co/pxm2cLiHWY https://t.co/wla3ZBB7nr

View on Twitter

DTB_BMJ @DTB_BMJ

September's DTB (available online 🖥️ and in print 📰) includes:
Adacanumab for Alzheimer's disease, antibiotic course length in primary care, chloramphenicol eye drops in children, and a review of dental health and medicines.

https://t.co/gHy7IqX8r3

View on Twitter

DTB_BMJ @DTB_BMJ

In September's podcast 📻we discuss aducanumab for Alzheimer's, antibiotic course length in primary care, dental health and medicines, and shared decision making.
https://t.co/R2YpUqsGKC

September's DTB is also available online 🖥️ and in print 📰
https://t.co/7o9wRWrKpB https://t.co/EJRugIWfWJ

View on Twitter

DTB_BMJ @DTB_BMJ

Dental implications of some commonly prescribed medicines.
Gursahib Sohal, Manas Dave and Neil Patel discuss what healthcare professionals need to know about the effects of medicines on oral health and dental management.

➡️ https://t.co/iWfVDEBXKg https://t.co/H1yOWfH6j9

View on Twitter